Relative benefits of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) are expected to accrue after complete bioresorption.
Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds: Implications for Manufacturers and Next Device Iterations
Capodanno, Davide
;Buccheri, Sergio;Capranzano, Piera;Tamburino, Corrado
2018-01-01
Abstract
Relative benefits of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) are expected to accrue after complete bioresorption.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
CIRCINTERVENTIONS.117.005768 (1).pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
578.68 kB
Formato
Adobe PDF
|
578.68 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
